Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 18

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 16
Chunk 18
---
     
    $
    502,751

The accompanying notes are an integral part of these financial statements.

F-9

Day One Biopharmaceuticals, Inc. 

Statements of Cash Flows

(in thousands)

    Year Ended December 31,

    2024

    2023

    2022

    Cash flows from operating activities:

    Net loss
     
    $
    (95,496
    )
     
    $
    (188,917
    )
     
    $
    (142,181
    )

    Adjustments to reconcile net loss to net cash used in operating activities:

    Acquired in-process research and development assets

    55,000

    3,000

    —

    Share-based compensation expense

    48,263

    39,341

    27,242

    Depreciation expense

    92

    36

    63

    Accretion of discounts on short-term investments, net

    (6,389
    )

    (10,078
    )

    (2,030
    )

    Amortization of intangible assets

    1,470

    —

    —

    Amortization of operating right-of-use asset

    467

    347

    468

    Gain from sale of priority review voucher

    (108,000
    )

    —

    —

    Changes in operating assets and liabilities:

    Accounts receivable, net

    (13,876
    )

    —

    —

    Inventory

    (3,243
    )

    —

    —

    Prepaid expenses and other current assets

    (4,556
    )

    (3,322
    )

    (546
    )

    Deposits and other long-term assets

    93

    255

    (300
    )

    Accounts payable

    686

    2,316

    (1,484
    )

    Accrued expenses and other current liabilities

    42,101

    10,574

    9,241

    Deferred revenue

    4,787

    —

    —

    Operating lease liability

    (273
    )

    (405
    )

    (347
    )

    Other long-term liability

    761

    —

    —

    Net cash used in operating activities

    (78,113
    )

    (146